BI 54903

DRUG5 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaHealthy

Phase 1

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

CompletedNCT01309139

Boehringer IngelheimHealthy

Start: 2011-03-31Updated: 2013-11-01

Phase 2

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

TerminatedNCT01396278

Boehringer IngelheimAsthma

Start: 2011-07-01End: 2011-12-14Updated: 2025-02-07

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

TerminatedNCT01397201

Boehringer IngelheimAsthma

Start: 2011-07-01End: 2011-12-23Updated: 2022-06-23

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

TerminatedNCT01397162

Boehringer IngelheimAsthma

Start: 2011-07-21End: 2011-12-23Updated: 2022-06-23

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

WithdrawnNCT01458886

Boehringer IngelheimAsthma

Start: 2011-11-30Updated: 2013-10-31